hormonal therapy

This page covers all hormonal therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting hormone receptors, EGFR, Estrogen receptor alpha (ESR1) and aromatase (CYP19A1), Androgen receptor (AR).

Targets

hormone receptors, EGFR · Estrogen receptor alpha (ESR1) and aromatase (CYP19A1) · Androgen receptor (AR) · Androgen receptor / GnRH receptor (depending on specific ADT agent)

Marketed (1)

• Novel hormonal therapy · Pfizer · Oncology

Phase 3 pipeline (4)

• tamoxifen + exemestane · Pfizer · Oncology
  This combination uses tamoxifen (a selective estrogen receptor modulator) and exemestane (an aromatase inhibitor) to block estrogen signaling through complementary pathways in hormone receptor-positive breast cancer.
• Antiandrogen Therapy · M.D. Anderson Cancer Center · Oncology
  Antiandrogen therapy blocks the effects of androgens (male hormones) by inhibiting androgen receptor signaling, thereby slowing or stopping the growth of androgen-dependent cancer cells.
• ADT (Standard of Care) · Aragon Pharmaceuticals, Inc. · Oncology
  ADT (Androgen Deprivation Therapy) suppresses testosterone production or blocks androgen receptor signaling to inhibit growth of androgen-dependent prostate cancer cells.
• Add-back therapy · Bio Genuine (Shanghai) Biotech Co., Ltd. · Gynecology / Endometriosis / Uterine Fibroids
  Add-back therapy restores hormonal levels that were suppressed by prior treatment, typically used to mitigate side effects of GnRH agonists in endometriosis or uterine fibroids.

Patent intelligence

• hormonal therapy patent landscape — aggregated cliff calendar, attackable patents, originator estates